Objective-The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. Approach and Results-Administration of OCA to chow-fed mice increased mRNA and protein levels of LDLR in the liver without affecting the sterol-regulatory element binding protein pathway. Profiling of known LDLR mRNA-binding proteins demonstrated that OCA treatment did not affect expressions of mRNA degradation factors hnRNPD (heterogeneous nuclear ribonucleoprotein D) or ZFP36L1 but increased the expression of Hu antigen R (HuR) an mRNA-stabilizing factor. Furthermore, inducing effects of OCA on LDLR and HuR expression were ablated in Fxr −/− mice. To confirm the post-transcriptional mechanism, we used transgenic mice (albumin-luciferase-untranslated region) that express a human LDLR mRNA 3′ untranslated region luciferase reporter gene in the liver. OCA treatment led to significant rises in hepatic bioluminescence signals, Luc-untranslated region chimeric mRNA levels, and endogenous LDLR protein abundance, which were accompanied by elevations of hepatic HuR mRNA and protein levels in OCA-treated transgenic mice. In vitro studies conducted in human primary hepatocytes and HepG2 cells demonstrated that FXR activation by OCA and other agonists elicited the same inducing effect on LDLR expression as in the liver of normolipidemic mice. Furthermore, depletion of HuR in HepG2 cells by short interfering RNA transfection abolished the inducing effect of OCA on LDLR expression. Conclusions-Our study is the first to demonstrate that FXR activation increases LDLR expression in liver tissue by a posttranscriptional regulatory mechanism involving LDLR mRNA-stabilizing factor HuR. Visual Overview-An online visual overview is available for this article.
C ardiovascular disease remains the leading cause of mortality and morbidity in United States and other parts of the world. There is compelling evidence from population-based data and clinical trials that reduction of low-density lipoprotein-associated cholesterol (LDL-C) is an effective strategy to prevent coronary heart disease, slow atherosclerotic development, and reduce damage and mortality. 1, 2 The number of low-density lipoprotein receptors (LDLR) expressed on the surface of hepatocytes is a major determinant of the circulating levels of LDL-C. 3, 4 Hepatic LDLR mediates the capture and uptake of LDL particles from the circulation and delivers the receptor-bound LDL-C to the endosomal system for degradation. Consistent with its key role in cholesterol homeostasis, the amount of LDLR in liver tissue is under complex and tight regulation by 3 different mechanisms: transcriptional, post-transcriptional, and post-translational. [5] [6] [7] The primary mode of LDLR regulation is at the transcriptional level and controlled by SREBP2 (sterol response element binding protein 2), which itself responds to intracellular cholesterol levels. 8, 9 Decreases in cellular cholesterol levels result in nuclear translocation of the active mature form of SREBP2 where it transactivates LDLR and other target genes, primarily via SRE motifs in their promoters. [9] [10] [11] In addition to increases in gene transcription to produce more transcripts, LDLR expression levels are dynamically regulated by changing its mRNA stability in response to extracellular stimuli, as well as to hepatic cholesterol levels. 12, 13 The stability of LDLR mRNA is controlled by regulatory sequences present in the 2.5 kb long stretch of the 3′ untranslated region (3′ UTR).
14 Within the 1 kb of the 5′ proximal section of the 3′ UTR, 3 mRNA destabilizing elements known as AU-rich elements (AREs) have been identified that are largely responsible for the rapid turnover rate of LDLR mRNA. 15, 16 Previous studies from our laboratory and other investigators have identified several ARE-BP (ARE-binding proteins) that interact with LDLR-ARE sequences and modulate the mRNA stability either positively or negatively. 13, [17] [18] [19] Among them, hnRNPD (heterogeneous nuclear ribonucleoprotein D) acts as a degradation factor for LDLR transcripts, and its expression in liver tissue is upregulated by hepatic cholesterol 13 and downregulated by the hypocholesterolemic compound berberine in rodent models. 17 Besides hnRNPD, a recent in vitro study identified zinc finger proteins ZFP36L1 and ZFP36L2 as LDLR mRNA destabilization factors. 20 Blocking the interaction between ZFP36L with LDLR-ARE led to increased LDLR protein levels in cultured cells while the in vivo function of ZFP36L on LDLR mRNA stability has not been reported. In contrast to the destabilizing ARE-BPs, some LDLR-ARE-binding proteins, including HuR, hnRNPI, and KSRP, were shown to increase LDLR expression in hepatic cell lines through their interactions with LDLR-ARE sequences. 18, 19 However, until the current study, no specific mRNA-binding proteins have been identified that are capable of increasing LDLR expression in liver tissue and reducing plasma LDL-C in animal models.
The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor regulating many aspects of bile acid and cholesterol metabolism. [21] [22] [23] FXR is abundantly expressed in the liver. It forms a heterodimer with retinoid X receptor to modulate expression of target genes by binding to DNA sequences referred as FXR response elements. 24, 25 In addition to directly inducing gene expression, FXR mediates the repression of many genes involved in bile acid synthesis indirectly through the upregulation of small heterodimer partner and V-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog G, which are FXR-induced transcriptional repressors. 26 Activation of hepatic FXR modulates numerous genes involved in lipid homeostasis, including CYP7A1, CYP8B1, BSEP, and scavenger receptor B1 (SR-B1), the major receptor for plasma high-density lipoprotein cholesterol (HDL-C). [27] [28] [29] Obeticholic acid (OCA) is a first-in-class FXR agonist being developed for primary biliary cholangitis, nonalcoholic steatohepatitis, and nonalcoholic fatty liver disease. 30 In adult patients with nonalcoholic steatohepatitis, OCA treatment improved the biochemical and histological features of nonalcoholic steatohepatitis but adversely affected plasma lipoprotein profiles in those patients by elevating total cholesterol (TC), LDL-C, and reducing HDL-C levels. 31 Interestingly, different from human studies, OCA treatments are associated with reductions in plasma TC, HDL-C, and in some cases, LDL-C in various animal models. [32] [33] [34] [35] [36] Although accumulating evidence has demonstrated that transcriptional activation of hepatic SR-B1 gene is the underlying mechanism for HDL-C reduction in OCA-treated animals, 34, 36 mechanisms underlying OCA-induced changes in plasma LDL-C levels in animal models versus humans have not been well understood. However, a recent new study conducted in chimeric mice with humanized liver showed that OCA treatment resulted in increased circulating LDL-C and decreased HDL-C in chimeric mice but not in control mice. 37 The increase in LDL-C was correlated with a significant reduction in LDLR protein levels in the liver of chimeric mice, implying that LDLR expression could be differentially regulated by FXR agonists in mouse liver and human liver tissue under in vivo conditions. Because liver LDLR is the key determinant for circulating LDL-C levels, it is of clinical importance to fully understand how FXR activation by OCA or other agonists modulates LDLR expression in mouse liver and in human liver cells. Such gained knowledge might help to identify the key factors that impact on LDLR expression in clinical settings of FXR agonists.
In this current study, by using wild-type (WT) and FXR knockout (Fxr −/− ) mice, we demonstrate that OCA increases LDLR expression in the liver of WT mice but not in FXR knockout mice under normolipidemic conditions. Importantly, OCA upregulates LDLR mRNA levels without affecting gene expression of other typical SREBP target genes. Further mechanistic investigations conducted in C57BL/6J mice and in LDLR 3′ UTR luciferase reporter mice reveal that OCAmediated FXR activation leads to stabilization of LDLR mRNA. This effect is achieved not by inhibiting mRNA degradation factors hnRNPD or ZFP36L1, instead OCA increased the expression of HuR in liver tissue in a FXR-dependent manner. Our in vitro studies conducted in human primary hepatocytes (HPH) and HepG2 cells further demonstrate that activations of FXR by OCA and by other synthetic agonists elicit the same inducing effect on LDLR expression as in liver tissues of chow-fed mice. Furthermore, depletion of HuR in HepG2 cells by short interfering RNAs (siRNA) transfection lowers basal levels of LDLR protein and abolishes the inducing effect of OCA on LDLR expression. Our studies identify HuR as a functional LDLR mRNA-stabilizing factor in mouse liver tissue and its regulation by FXR signaling pathway.
Materials and Methods
The authors declare that all supporting data are available within the article (and its online-only Data Supplement). ) were purchased from the Jackson Laboratory (Bar Harbor, ME) and were maintained on a normal chow diet for the entire study. Where indicated, 10-to 12-week-old mice were gavaged with either vehicle (0.5% carboxymethyl cellulose; Sigma-Aldrich, St. Louis, MO) or vehicle containing OCA (40 mg/kg) for 7 to 10 days.
Animals, Diet, and Drug Treatment
In a separate experiment, mice were fed a high-fat and high-cholesterol diet (HFHCD) containing 40% calories from fat and 0.5% cholesterol (no. D12107C, Research Diets, Inc, New Brunswick, NJ) for 2 weeks. Continuous on the HFHCD, 8 mice with similar levels of serum cholesterol were divided into 2 groups and were treated with OCA (40 mg/kg per day) or vehicle for 14 days.
After the last dosing, all animals were fasted for 4 to 5 hours and then euthanized for collection of serum and liver tissues. Female mice were not used in this study to avoid the influence of fluctuation of estrogen levels on hepatic LDLR expression.
Bioluminescence Imaging of Alb-Luc-UTR Mice and OCA Treatment
Albumin (Alb)-luciferase (Luc)-UTR transgenic mice were generated and bred in the Veterinary Medical Unit of Veterans Affairs Palo Alto Health Care System. Bioluminescence was detected with the In Vivo Imaging System (Xenogen, Alameda, CA) as previously described. 17 Alb-Luc-UTR male mice received an intraperitoneal injection of 50 mg/kg D-luciferin 10 minutes before imaging and were anesthetized with isoflurane during imaging. Photons emitted from living mice were acquired as photons per second/cm 2 per steradian by using Living Image software (Xenogen) and were integrated for 60 seconds for photon quantification. A region of interest was manually selected and kept constant within all experiments. The signal intensity was converted into photons per s/cm 2 per steradian. Before the treatment, baseline bioluminescence imaging was obtained from all animals. Six mice with similar signal intensities were divided into 2 treatment groups of OCA (40 mg/kg per day) and vehicle. After 5 days of treatment, bioluminescence imaging was recorded. After 10 days of treatment, bioluminescence imaging was recorded before euthanizing the animals for fasting serum and liver tissue collection.
Cells and Reagents
Human hepatoma HepG2 cells were obtained from ATCC. HPHs were obtained from Invitrogen. FXR agonists GW4064 and FXR-450 were purchased from Sigma, and OCA was provided by Intercept Pharmaceuticals. pHrodo-Green LDL (Cat. No. L34355) was purchased from ThermoFisher Scientific.
Culture of Primary Hepatocytes
HPHs were seeded on collagen coated plates at a density of 1×10 
LDL Uptake
HepG2 cells were plated in 6-well culture plates (1×10 6 cells/well) for 24 hours. After 24 hours (at ≈70% confluence), medium was changed to minimal essential medium (MEM) supplemented with 0.5% fetal bovine serum (FBS). After overnight incubation, cells were treated with FXR agonists at desired concentrations overnight. pHrodo-Green LDL (10 μg/mL) was incubated with cells for 3 hours, and cells were washed twice in assay buffer solution (PBS plus 3% BSA). Fluorescent-labeled LDL uptake was examined with a fluorescent microscope, and pictures were taken for 10 fields of view in each well. The fluorescence intensities were subsequently quantified using NIS-Elements imaging software.
siRNA Transfection siRNAs against human HuR (Cat. No. SI00300139, SI03246551) and control siRNA (Cat. No. 12935-100) were purchased from Qiagen and ThermoFisher Scientific. siRNAs were transfected into HepG2 cells in suspension using siPORT NeoFX transfection reagent (Invitrogen) at a final concentration of 30 nmol/L. After overnight transfection, medium was replaced with fresh MEM medium containing 10% FBS. After 36 hours, cells were starved overnight in 0.5% FBS-containing MEM medium, and cells were treated with either vehicle control (dimethyl sulfoxide) or OCA (10 μmol/L) for 24 hours before cell lysis. siRNA sequences are listed in Table I in the online-only Data Supplement.
Measurement of Serum Lipids
Standard enzymatic methods were used to determine TC, HDL-C, and triglyceride (TG) in individual serum samples with kits purchased from Stanbio Laboratory.
High-Performance Liquid Chromatography Separation of Serum Lipoprotein Cholesterol and TGs
For the study of C57BL/6J mice, after 10 days of treatment, 50 μL of serum sample from 2 animals of the same treatment group of day 10 were pooled together and were analyzed for cholesterol and TG levels in different lipoprotein fractions after high-performance liquid chromatography separation at Skylight Biotech, Inc as previously described.
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Measurement of Hepatic Lipids
Lipids were treated from liver tissue according to the Folch method. 38 Briefly, 30 mg of frozen liver tissue or 20 mg of dried feces were homogenized in 1 mL chloroform/methanol (2:1). After homogenization, lipids were further extracted by rocking samples overnight at room temperature, followed by centrifugation at 5000 rpm for 10 minutes. Supernatant was transferred to a new tube and mixed with 0.2 mL 0.9% saline. The mixture was then centrifuged at 2000 rpm for 5 minutes, and the lower phase containing the lipids was transferred into a new tube. The lipid phase was dried overnight and dissolved in 0.25 mL isopropanol containing 10% triton X-100. TC and triglycerides were measured using kits from Stanbio Laboratory.
Measurement of Liver and Serum Total Bile Acids
Twenty milligram of frozen liver were homogenized and extracted in 1 mL of 75% ethanol at 50°C for 2 hours. 34 The extract was centrifuged, and the supernatant was used to measure total bile acids using a kit from Diazyme, Poway, CA. Serum total bile acids were measured by the same kit from Diazyme.
RNA Isolation and Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction (PCR)
Total RNA was extracted from liver tissue or cells using the Quick RNA mini Prep kit (Zymo Research) and was reverse-transcribed into cDNA. Real-time PCR was then performed with duplicate or triplicate measurements from each cDNA sample in an ABI 7900HT Sequence Detection system using SyBr Green PCR Master mix (Life Technologies), and PCR primers specific for each gene being amplified. The ΔΔCT method was used to quantify relative expression of target mRNAs normalized to that of GAPDH in each sample. Primer sequences are listed in Table I in the online-only Data Supplement.
Western Blot Analysis
Approximately 30 mg of frozen liver tissue was homogenized in 0.3 mL radioimmunoprecipitation assay buffer containing 1 mmol/L phenylmethylsulfonyl fluoride and protease inhibitor cocktail (Roche), and 75 μg of homogenate proteins from individual liver samples were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Antibodies used in Western blot analysis are listed in Major Resource Table. All primary antibodies were used at 1:1000 dilution and the secondary antibody dilution was 1:10000. Immunoreactive bands of predicted molecular mass were visualized using SuperSignal West Substrate (ThermoFisher Scientific) and quantified with the Alpha View Software with normalization by signals of β-actin.
Statistical Analysis
GraphPad Prism 7 was used to calculate averages and errors, generate graphs, and perform statistical tests. Unless otherwise indicated, after passing the normality and equal variance tests, a 2-tailed and unpaired Student t test was used to compare 2 groups, and the ANOVA model with Dunnett multiple comparison post-test was used to compare groups of ≥3. Graphs represent mean±SEM unless otherwise indicated. *P<0.05, **P<0.01, ***P<0.001. A P<0.05 was considered significant.
Results
Reductions of Serum HDL-C and LDL-C Levels by OCA Treatment
It was reported that FXR agonists have different potencies to human FXR versus mouse FXR, and OCA has a lower EC 50 value to mouse FXR as compared with human FXR. 32 To determine effects of OCA on plasma cholesterol metabolism in chow-fed mice, initially we conducted pallet studies of different doses of OCA and observed that OCA at a daily dose of 10 mg/kg did not affect serum cholesterol levels nor hepatic mRNA levels of FXR-modulated genes ( Figure I in the onlineonly Data Supplement), but OCA treatments at 40 and 60 mg/ kg both effectively lowered serum TC levels and increased hepatic Sr-b1 mRNA expression ( Figure II in the online-only Data Supplement). Thus, we performed subsequent studies with OCA at 40 mg/kg per day dose.
Mice fed a normal chow diet were orally treated with OCA (n=6) or vehicle (n=6) for 10 days. OCA treatment did not affect body weight or food intake ( Figure IIIA and IIIB in the online-only Data Supplement), but it lowered serum TC and HDL-C by 30.5% (P<0.01) and 21.9% (P<0.01), respectively, as compared with vehicle control ( Figure 1A and 1B) . In contrast to serum cholesterol levels, individual measurements of serum TG levels showed no statistical changes by OCA treatment (Figures IIIC and IV in the online-only Data Supplement).
Next, we performed high-performance liquid chromatography separation of pooled samples that combined 2 serum samples together from the same treatment group. Results showed that the decrease in TC was driven by reductions in HDL-C (−20%; P<0.01) and LDL-C (−43%; P<0.05) without changing cholesterol levels in very-low-density lipoprotein fractions ( Figure 1C ; upper panel of Figure V in the onlineonly Data Supplement). High-performance liquid chromatography analysis of lipoprotein-TG fractions ( Figure 1D ; lower panel of Figure V in the online-only Data Supplement) did not detect meaningful changes, which was consistent with individual TG measurements. In addition, activation of FXR by OCA reduced liver total bile acids concentration ( Figure 1E ) and serum total bile acids levels ( Figure 1F ). Analysis of liver tissue showed that FXR activation by OCA did not change liver cholesterol amount but reduced liver TG content significantly ( Figure 1G and 1H) , Altogether, these data demonstrate that FXR activation by OCA led to reductions of serum HDL-C and LDL-C levels in normolipidemic mice.
OCA Upregulates Hepatic LDLR mRNA and Protein Levels Without Activating SREBP Pathway
Western blot analysis of hepatic LDLR and SR-B1 expressions from individual liver homogenates demonstrated that the reduction of serum LDL-C by OCA was accompanied by a 35% (P<0.01) increase in liver LDLR protein levels, and the level of HDL receptor SR-B1 was increased by 67% (P<0.001; Figure 2A ). Although activation of Sr-b1 gene transcription by FXR agonists in mice is well documented, 35, 39, 40 mechanisms underlying effects of FXR agonists on LDLR expression have not been well elucidated. We performed quantitative reverse transcription PCR to measure mRNA levels of several SREBP target genes and Sr-b1 ( Figure 2B ). As expected, Sr-b1 mRNA levels were elevated to 1.9-fold of vehicle control by OCA treatment. Interestingly, OCA increased Ldlr mRNA levels significantly to 1.7-fold of control, whereas other typical SREBP2 target genes, such as Pcsk9 and Hmgcr, were unaffected by OCA. These results suggest that OCA did not increase Ldlr transcription nor inhibit proprotein convertase subtilisin/kexin type 9-mediated degradation of LDLR protein in the liver of normolipidemic mice.
To explore the possibility of a post-transcriptional effect, we examined hepatic protein levels of known LDLR mRNA-stabilizing factor HuR 19 and destabilizing factors hnRNPD 13, 17, 18 and ZFP36L. 20 OCA treatment did not affect hnRNPD but significantly increased HuR protein levels to 40% of control (P<0.001) and slightly elevated ZFP36L protein levels ( Figure 2C ). Hepatic gene expression analysis of mRNA-binding proteins largely corroborated the results of Western blot analysis, confirming the increase in HuR mRNA expression, as well as Zfp36l1 ( Figure 2D) . A recent study in mice has identified Zfp36l1 as a FXR target gene and a degradation factor for Cyp7a1 transcript that encodes a key enzyme in bile acid synthesis. 41, 42 The increased expression of Zfp36l1 by OCA treatment observed in our study is consistent with that report. However, the coordinated increases in LDLR and HuR at both protein and mRNA levels by OCA treatment suggested that OCA-induced upregulation of LDLR expression in liver tissue is mediated through HuR, an LDLR mRNAstabilizing factor not involving ZFP36L1.
To prove that the induction of HuR by OCA is mediated through FXR, we analyzed HuR and LDLR protein expressions in liver samples of Fxr −/− mice and their WT littermates that were treated with either vehicle or OCA (40 mg/ kg per day) for 7 days. OCA treatment increased hepatic HuR and LDLR protein levels in WT mice but not in Fxr −/− mice ( Figure 2E and 2F) . We also confirmed the induction of ZFP36L1 by OCA treatment in a FXR-dependent manner ( Figure VI in the online-only Data Supplement).
Next, we further examined the coordinated upregulation of LDLR and HuR by OCA-induced FXR activation in C57BL/6J mice fed an HFHCD. OCA treatment effectively increased liver SR-BI expression at both mRNA and protein levels, which was correlated with a large effect on lowering serum TC and HDL-C levels ( Figure VII in the online-only Fasted serum samples were collected at day 10. A, Serum TC; B, serum HDL-C; C and D, cholesterol and triglycerides distributions in high-performance liquid chromatography-separated lipoprotein factions from mice treated with vehicle or OCA; E, liver total bile acids contents; F, serum bile acids levels. G, Liver total cholesterol amounts, and (H) liver total triglycerides. In B-H, statistical significance was determined by 2-tailed and unpaired Student t test. n=6 mice in each group. In A, statistical significance was determined by nonparametric Mann-Whitney test. n=6 mice in each group. *P<0.05, **P<0.01, ***P<0.001. Data Supplement). Interestingly, under the hyperlipidemic condition, OCA treatment did not affect HuR mRNA and protein levels which were correlated with unchanged LDLR expression. Furthermore, the expression levels of ZFP36L1/2 did not differ between vehicle and OCA-treated liver tissues, suggesting that OCA did not upregulate LDLR mRNA-binding proteins in cholesterol-enriched liver tissues.
In Vivo Demonstration of OCA-Induced Liver LDLR Expression via mRNA 3′ UTR
To further investigate the underlying mechanism of OCAmediated increase in hepatic LDLR expression under normolipidemic condition, we used transgenic mice (Alb-Luc-UTR) that express the Luc-LDLR3′ UTR reporter gene (Luc-UTR) under the control of the liver-specific Alb promoter. 17 AlbLuc-UTR is a unique in vivo model to study the function of the 3′ UTR in mediating LDLR mRNA decay in liver tissue. Before OCA treatment, baseline bioluminescence imaging was obtained from all animals ( Figure VIIIA in the online-only Data Supplement). Six mice with similar signal intensities were divided into 2 treatment groups of OCA (40 mg/kg per day) and vehicle. Figure 3A shows live bioluminescent imaging of vehicle and OCA-treated mice after 5 days of gavaging. Figure 3B summarizes imaging results (mean±SEM) showing that OCA increased bioluminescence signal 1.8-fold over the control (P<0.01). At the end of 10-day treatment before euthanizing animals, we also conducted live imaging which again showed higher luminescent signals in Western blot analysis confirmed the elevation of LDLR and HuR protein abundances in liver tissues of Alb-Luc-UTR mice after 10 days of OCA treatment ( Figure 3C ). Using real-time quantitative reverse transcription PCR, we analyzed liver mRNA levels of Luc-UTR transgene and endogenous Ldlr mRNA along with panels of LDLR AREBPs, SREBP, and FXR target genes ( Figure 3D-3F) . These results further confirmed that OCA specifically increased Luc-UTR, Ldlr, and HuR mRNA levels without affecting mRNA levels of genes in the SREBP pathway or liver Ldlr mRNA degradation factor hnRNPD. Effects of OCA on modulating gene expression of Cyp7a1 and Cyp8b1 further validated the engagement of FXR in OCA-treated Alb-Luc-UTR mice. Measurements of serum and hepatic lipids showed significant reduction of circulating TC and no accumulations of cholesterol in the liver and unchanged serum TG levels in these transgenic mice by OCA treatment (Figure 4) , resembling the changes in lipid profile observed in OCA-treated C57BL/6J mice (Figure 1 ).
FXR Activation Increases LDLR Expression in Human Liver Cells
To determine whether the observed inducing effects of FXR on hepatic LDLR expression is limited to mouse species, we examined the response of human liver cells to OCA treatment. Initially, HPH derived from 3 different donors (4055B, 4105A, 4034) were treated with OCA for 24 hours at 1 and 10 μmol/L doses. OCA induced a dose-dependent increase in LDLR mRNA levels in all tested HPHs, whereas mRNA levels of HMGCR, SREBP1, and SREBP2 were unchanged ( Figure 5A-5C ). We further examined effects of FXR activation by other synthetic agonists GW4064 and FXR-450 along with OCA on LDLR mRNA and protein expressions in HPH donor 4122B. All 3 agonists at effective doses elevated LDLR mRNA and protein levels to similar extents ( Figure 5D and 5E). Again, we observed a coordinated elevation in mRNA expressions of LDLR and its mRNA-stabilizing factor HuR ( Figure 5F ) in HPH donor 4269.
To further examine the role of HuR in FXR-mediated LDLR expression, we used siRNA technology and human hepatoma-derived HepG2 cells, which have higher transfection rates than HPHs. Like HPHs, treatment of HepG2 cells with OCA increased LDLR and HuR mRNA and protein levels in a dose-dependent manner (Figure 6A and 6B; Figure  IX in the online-only Data Supplement). Furthermore, LDLRmediated LDL uptake assays showed that the labeled LDL intracellular fluorescence intensities in HepG2 cells were significantly increased on FXR activation by OCA and by GW4064 ( Figure 6C and 6D) , suggesting that the increased LDLR protein abundance by FXR activation translated into a higher functional activity of receptor-mediated uptake of LDL particles from the culture medium.
Next, we transfected HepG2 cells in triplicate wells with either a control scrambled siRNA or with a siRNA targeted to the protein coding region of HuR transcript (siHuR-1) for 48 hours with the absence or presence of OCA in the past 24 hours before cell lysis. Compared with control siRNA, transfection of HuR siRNAs significantly reduced cellular HuR and LDLR protein amounts and abolished the OCAinduced increase in LDLR protein levels ( Figure 6E and 6F) . Collectively, these results obtained from HPHs of 5 different donors and HepG2 cells corroborated our findings in liver tissues of WT and transgenic mice fed a normal chow diet. Combining the in vitro data with in vivo results, our studies Figure 5 . Sterol-regulatory element binding protein 2-independent induction of low-density lipoprotein receptor (LDLR) mRNA expression by farnesoid X receptor (FXR) agonists in human primary hepatocytes derived from 5 different donors. A-C, Human primary hepatocytes (HPHs) of 3 different donors (HPH 4055B, HPH 4105A, HPH 4034) were treated with obeticholic acid (OCA) at 1 and 10 µmol/L for 24 h before isolation of total RNA. Triplicate wells were used in each condition. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to measure relative mRNA levels of indicated genes with duplicate measurement of each cDNA sample. D and E, HPH 4122B were treated with FXR agonists at indicated concentrations for 24 h before isolation of total RNA or total lysates. Duplicate wells were used in each condition. LDLR protein abundance was analyzed by Western blotting. Values represent mean of densitometric measurements of LDLR normalized to β-actin signal from duplicate samples per treatment. In D, Q-PCR was performed to measure relative LDLR mRNA levels. Individual cDNA samples were measured in duplicate, and a total of 4 q-PCR measurements for each condition. F, HPH 4269 were treated with OCA (10 µmol/L) for 24 h before isolation of total RNA. Triplicate wells were used in each condition. Q-PCR was performed to measure relative mRNA levels of indicated genes with duplicate measurement of each cDNA sample. In A-D, statistical significance was determined with 1-way ANOVA with Dunnett multiple comparison post-test. In F, statistical significance was determined by 2-tailed unpaired Student t test. n=3 in each group. *P<0.05, **P<0.01, and ***P<0.001 compared with the dimethyl sulfoxide (DMSO) control.
suggest that upregulation of hepatic LDLR expression via HuR-mediated mRNA stabilization is likely a common property of FXR regardless of species.
Discussion
Many studies have established key roles of FXR in bile acid and cholesterol metabolism. 43, 44 The important new findings of our current study are that FXR activation directly regulates liver LDLR expression and impacts plasma LDL-C levels in normolipidemic mice through a molecular mechanism different from other nuclear receptors such as peroxisome proliferatoractivated receptors, 45 SREBP2, 11 and LXR 7 that regulate LDLR gene expression at transcriptional levels or post-translational levels. In contrast, ligand-induced activation of FXR leads to stabilization of LDLR transcript. This is achieved by enhancing the expression of HuR, the LDLR mRNA-stabilizing protein.
It was first reported in 2002 by Nakahara et al 46 that bile acids, which are endogenous FXR activators, increase LDLR A, HepG2 cells in triplicate wells were cultured overnight in culture medium containing 0.5% fetal bovine serum (FBS), followed by treatment of obeticholic acid (OCA) at 1 and 10 µmol/L doses for 24 h. Quantitative reverse transcription polymerase chain reaction was performed to measure relative LDLR and HuR mRNA levels. After normalization with GAPDH mRNA levels, the relative levels are presented. Statistical significance was determined by 1-way ANOVA with Dunnett multiple comparison post-test. n=3 in each group. **P<0.01 and ***P<0.001 compared with the dimethyl sulfoxide (DMSO) control. B, Western blotting with antibodies to LDLR and β-actin was conducted by analyzing individual homogenates from HepG2 cells treated with DMSO (control), OCA (at indicated doses), or GW4064 (1 µmol/L). C, HepG2 cells were seeded into 6-well plates at a density of 0.5×10 6 cells/well. After 24 h (at ≈70% confluence), medium was changed to minimal essential medium supplemented with 0.5% FBS. After overnight incubation in this low-serum containing medium, cells were treated vehicle or with GW4064 (1 µmol/L) or with OCA (10 µmol/L) for 16 h. pHrodo-Green LDL (10 μg/mL) was incubated with cells for 3 h, and cells were washed 3× by cold PBS. Green-LDL uptake was examined with a fluorescent microscope, and pictures were taken for 10 fields of view in each well. D, Fluorescence intensities were semiquantified using NIS-Elements imaging software. The relative fluorescent intensity from control samples was arbitrarily set to 1. Statistical significance was determined by 1-way ANOVA with Dunnett multiple comparison post-test. n=10 in each group. **P<0.01 and ***P<0.001 compared with the DMSO control. E and F, HepG2 cells in triplicate wells were transfected with 30 nmol/L of control or siHuR siRNA for 2 d followed by OCA treatment of 24 h before cell lysis for Western blotting with anti-LDLR, anti-HuR, and anti-β-actin antibodies. Values represent mean±SEM of densitometric measurements of LDLR or HuR normalized to β-actin signal from triplicate samples per treatment condition. Statistical significance was determined by 2-tailed and unpaired Student t test. n=3 in each group. **P<0.01 compared with the DMSO control.
expression in cultured human cells by stabilizing LDLR mRNA. Nearly a decade later, ARE1 site in the 3′ UTR was characterized as the responsive region to mediate chenodeoxycholic acid-induced stabilization of LDL receptor mRNA. 47 Subsequently, in a separate study, it was reported that compound AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an AMP kinase activator, increased the LDLR mRNA and protein levels in HepG2 cells through a post-transcriptional mechanism that stabilized the mRNA, and it was further shown that AICAR-induced LDLR mRNA stabilization resulted from modulating the interaction between ARE1 and HuR and 2 other unknown cytoplasmic AREBPs. 19 Taken from these few existing reports of cell culture studies, it became clear that whether and how activations of FXR by endogenous ligands or synthetic ligands modulate LDLR expression in liver tissue in vivo needed to be thoroughly investigated in animal models.
In this study, we first showed that OCA treatment lowered plasma HDL-C and LDL-C levels that were accompanied by increased expressions of hepatic HDL receptor SR-B1 and LDLR at both mRNA and protein levels in chow-fed mice. Importantly, OCA elevated Ldlr mRNA abundance without inducing the expression of other SREBP target genes. These data from C57BL/6 mice suggested a post-transcriptional regulatory mechanism. To prove this, we used Alb-Luc-UTR mice that express the luciferase-LDLR3′ UTR reporter gene driven by the liver-specific albumin promoter. 17 In these transgenic mice, OCA treatment increased luminescent signal captured in live animals and elevated the Luc-UTR transgene mRNA, as well as endogenous Ldlr mRNA and protein levels in the liver, which provided the first evidence of LDLR mRNA stabilization in liver tissue by FXR activation.
Our previous in vivo studies identified ARE-BP hnRNPD as a major degradation factor for liver LDLR transcripts. 13 We showed that LDLR expression and hnRNPD expression were reciprocally correlated in liver tissues of mice and hamsters. We further showed that reduced expression of hnRNPD in liver tissue of berberine-treated mice was correlated with decreased serum LDL-C levels by the natural hypolipidemic compound. 17 Besides hnRNPD, in 2014, ZFP36L1 and ZFP36L2 were identified as degradation factors for LDLR transcripts in a cell culture study. 20 Interestingly, a recent study reported that ZFP36L1 is an FXR target gene in mice and participates in FXR-induced suppression of Cyp7a1 mRNA, encoding a key enzyme in the bile acid synthetic pathway. 40 Thus, to understand how OCA could stabilize liver LDLR mRNA, we initially focused our investigation on hnRNPD, ZFP36L1, and HuR. In C57BL/6J mice, OCA treatment did not affect hnRNPD mRNA or protein levels. The protein expression of ZFP36L1 was only slightly increased in OCAtreated liver tissue despite a 2-fold increase in its mRNA levels. In contrast to these 2 degradation factors, HuR mRNA and protein were both significantly increased by OCA treatment in the liver of C57BL/6J mice. To demonstrate a FXRdependent effect, we examined LDLR and HuR expression in livers of Fxr −/− mice and the littermate control (Fxr +/+ ) that were treated with OCA or vehicle for 7 days. 35 The results clearly showed the ablation of OCA induction of both proteins in FXR knockout mice.
The induction of hepatic HuR expression was further observed in the transgenic mice after OCA treatment. Thus, in all 3 FXR WT mouse models (C57BL/6J, Alb-Luc-UTR, and Fxr +/+ ), OCA induced increases in HuR and LDLR to comparable levels. Although we could not exclude a counter effect of ZFP36L1 in destabilizing LDLR transcripts on FXR activation, the observed increases in LDLR mRNA and protein levels in OCA-treated WT and transgenic mice strongly suggest a positive role of HuR in the stabilization of LDLR transcripts in liver tissue under normolipidemic conditions. In HFHCDfed mice, we did not detect inductions of HuR and LDLR by OCA treatment which contrast to the effect of OCA on SR-BI, whose expression is induced by OCA under both diet conditions. The underlying mechanism of the impact of hepatic cholesterol levels on HuR expression will be investigated in our future studies.
To extend our findings in mice to human studies of FXR, we examined effects of OCA, a clinical FXR agonist, on LDLR expression in HPH. Using HPH derived from 5 different donors and HepG2 cells, we demonstrate that under normal cell culture conditions, FXR activations by OCA and other synthetic agonists GW4064 and FXR-450 induce LDLR mRNA expression without activating the SREBP pathway. Finally, we showed that siRNA-mediated knockdown of HuR in HepG2 cells led to marked reductions in baseline LDLR protein levels and abolished OCA-induced LDLR expression. Interestingly, it was shown in the previous report of Yashiro et al 19 that siRNA-mediated knockdown of HuR in HepG2 cells lowered the baseline and abolished the AICAR-induced elevation of LDLR mRNA levels, which were similar to our results of LDLR protein levels in HuR-depleted HepG2 cells. They further reported that AICAR-induced LDLR mRNA stabilization through HuR was dependent on the activation of ERK (extracellular signal-regulated kinase) signaling pathway. In our future investigations, we will examine the effects of OCA on ERK signaling pathway in the liver of mice fed a normal chow diet as well as mice fed an HFHCD to determine whether the inability to activate ERK pathway is the causal factor for unchanged HuR and LDLR expression in HFHCD-fed mice on OCA treatment. Nevertheless, combining the in vivo data with in vitro results of hepatic cells, our studies identify HuR as one stabilizing factor for LDLR mRNA in liver tissue and its upregulation by activated nuclear receptor FXR.
It is worthy to note that in both WT mice and transgenic mice fed a normal chow diet, we did not detect any accumulations of liver cholesterol after OCA treatment, which might explain the unchanged gene expression of the SREBP pathway. Under such conditions, the increased mRNA stability translated into more functional activities of LDLR and led to enhanced removal of circulating LDL-C. However, it is highly possible that FXR regulates LDLR expression by more than one mechanism. In a chimeric mouse model of humanized liver (PXB mice), OCA treatment lowered liver LDLR mRNA and protein levels, which were accompanied by increased serum TC and LDL-C. In those chimeric mice fed a normal chow diet, OCA treatment led to increased hepatic cholesterol in chimeric mice but not in control mice. Consequently, the processing of SREBP2 was inhibited, which led to the suppression of LDLR gene expression. These observations more closely parallel the changes observed in humans treated with OCA. It is possible that under conditions of a suppressed SREBP pathway, the increase in LDLR mRNA stability would not be able to override the decrease in gene transcription, thus leading to the net decrease in LDLR protein expression. Alternatively, the FXR-HuR-LDLR pathway might be unique to liver tissues of mice and might not operate in human liver tissues and the direct evidence of this pathway in human liver in vivo in currently lacking. It is also possible that some other FXR target genes are differentially modulated in human liver versus mouse liver that might contribute to the accumulation of hepatic cholesterol in chimeric mouse and presumably human liver but not in the liver of control mice.
In summary, we have demonstrated that under normolipidemic conditions, FXR activation increases liver LDLR expression through a post-transcriptional regulatory mechanism in mice and in cultured human liver cells. We further identify HuR as the LDLR mRNA-stabilizing factor in liver tissue and the mediator of FXR-induced upregulation of LDLR expression. Our studies provide new insight into the regulation of LDLR expression by the bile acid-activated nuclear receptor FXR.
